In order to elucidate the focus of Venture Capital funding in the Biotechnology sector this year, Evolution Analysts have assessed the deals carried out by the Top 25 US Venture
For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that highlight the rise and
Evolution’s 2015 Biopharmaceutical IPO Analysis was featured in a recent article on Forbes. Science & Business correspondent Arlene Weintraub’s article, titled “Will Wall Street Volatility Dampen The Sizzling Biotech IPO
In the first half of 2015 fifty therapeutics companies finalised their IPOs, raising over $5.17 billion across multiple global exchanges. Evolution Global Talent Attraction analysed the therapeutic targets and IPO
NantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer,
Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will leverage T cell therapeutic
